Home
/
Prelude Therapeutics Inc
/
Financials
/
Quarterly
Prelude Therapeutics Inc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Prelude Therapeutics Inc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$6.50M
Nov 12, 2025
Q3
2025
Sep 30, 2024
$3.00M
Nov 12, 2025
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($19.73M)
Nov 12, 2025
Q3
2025
Jun 30, 2025
($31.23M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($31.23M)
Aug 14, 2025
Q3
2025
Mar 31, 2025
($32.09M)
Nov 12, 2025
Q1
2025
Mar 31, 2025
($32.09M)
May 6, 2025
Q2
2025
Mar 31, 2025
($32.09M)
Aug 14, 2025
Q3
2025
Sep 30, 2024
($32.27M)
Nov 12, 2025
Q3
2025
Jun 30, 2024
($34.74M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($34.74M)
Aug 14, 2025
Q2
2025
Mar 31, 2024
($31.43M)
Aug 14, 2025
Q3
2025
Mar 31, 2024
($31.43M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($31.43M)
May 6, 2025
Q3
2024
Sep 30, 2023
($30.61M)
Nov 6, 2024
Q3
2024
Jun 30, 2023
($30.43M)
Nov 6, 2024
Q1
2023
Jun 30, 2023
($30.43M)
Aug 3, 2023
Q2
2024
Jun 30, 2023
($30.43M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($27.72M)
May 7, 2024
Q2
2024
Mar 31, 2023
($27.72M)
Aug 12, 2024
Q3
2024
Mar 31, 2023
($27.72M)
Nov 6, 2024
Q3
2023
Sep 30, 2022
($29.96M)
Nov 1, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($20.42M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($32.19M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($34.61M)
May 6, 2025
Q3
2025
Sep 30, 2024
($34.38M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($37.16M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($34.34M)
May 6, 2025
Q3
2024
Sep 30, 2023
($33.39M)
Nov 6, 2024
Q1
2023
Jun 30, 2023
($32.40M)
Aug 3, 2023
Q2
2024
Jun 30, 2023
($32.40M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($29.12M)
May 7, 2024
Q3
2023
Sep 30, 2022
($30.41M)
Nov 1, 2023
Q1
2023
Jun 30, 2022
($29.46M)
Aug 3, 2023
Q2
2022
Jun 30, 2022
($29.46M)
Aug 9, 2022
Q1
2023
Mar 31, 2022
($30.29M)
May 8, 2023
Q3
2022
Sep 30, 2021
($30.84M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($27.92M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($21.97M)
May 10, 2022
Q3
2021
Sep 30, 2020
($18.14M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($11.44M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($9.74M)
May 11, 2021